Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

89.23
+0.77500.88%
Volume:783.68K
Turnover:69.90M
Market Cap:6.14B
PE:-28.62
High:90.93
Open:88.45
Low:87.01
Close:88.45
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:0.92
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:59.65
PE(LYR):-28.69

Loading ...

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Rigel Pharmaceuticals Q2 Revenue Rises on Strong Product Demand

Reuters
·
Aug 05

Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth

Reuters
·
Aug 05

Rhythm Pharma Executives to Speak at Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

Rhythm Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Rhythm Pharma's Obesity Drug Shows Promise for Brain Tumor-Related Weight Condition

Reuters
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Stock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data

Stock Track
·
Aug 04

Rhythm Pharma Q2 FY26 Net Loss Widens to $50.4 Million; Revenue Rises 47% to $71.3 Million

Reuters
·
Aug 04

Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate

Benzinga Earnings
·
Aug 04

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q2 Net Loss $0.73 a Share, vs. FactSet Est of $0.83 Loss

MT Newswires Live
·
Aug 04

Rhythm Pharmaceuticals Q2 Net Income USD -49.298 Million Vs. IBES Estimate USD -55.5 Million

Reuters
·
Aug 04

Rhythm Pharmaceuticals Q2 Basic EPS USD -0.73

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Estimates Non-Gaap Operating Expenses $363 Mln-$397 Mln for Year Ending Dec 31, 2026

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial That Showed Rm-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Two Participants Discontinued Rm-718 Treatment Due to Adverse Events

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports 11.6% Mean Bmi Reduction at Week 16 in Phase 2 Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Rm-718 Generally Well Tolerated with Most Common Adverse Events Injection Site Reactions, Nausea, Vomiting

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports Two Mild Cases of Injection Site Hyperpigmentation in Rm-718 Trial

THOMSON REUTERS
·
Aug 04